Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays

Abstract There is a plethora of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serological tests based either on nucleocapsid phosphoprotein (N), S1-subunit of spike glycoprotein (S1) or receptor binding domain (RBD). Although these single-antigen based tests demonstrate high clinical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christos Fotis, Nikolaos Meimetis, Nikos Tsolakos, Marianna Politou, Karolina Akinosoglou, Vaia Pliaka, Angeliki Minia, Evangelos Terpos, Ioannis P. Trougakos, Andreas Mentis, Markos Marangos, George Panayiotakopoulos, Meletios A. Dimopoulos, Charalampos Gogos, Alexandros Spyridonidis, Leonidas G. Alexopoulos
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/858a40ad7d234e85a90d69d2e74774df
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:858a40ad7d234e85a90d69d2e74774df
record_format	dspace
spelling	oai:doaj.org-article:858a40ad7d234e85a90d69d2e74774df2021-12-02T11:45:01ZAccurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays10.1038/s41598-021-86035-22045-2322https://doaj.org/article/858a40ad7d234e85a90d69d2e74774df2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86035-2https://doaj.org/toc/2045-2322Abstract There is a plethora of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serological tests based either on nucleocapsid phosphoprotein (N), S1-subunit of spike glycoprotein (S1) or receptor binding domain (RBD). Although these single-antigen based tests demonstrate high clinical performance, there is growing evidence regarding their limitations in epidemiological serosurveys. To address this, we developed a Luminex-based multiplex immunoassay that detects total antibodies (IgG/IgM/IgA) against the N, S1 and RBD antigens and used it to compare antibody responses in 1225 blood donors across Greece. Seroprevalence based on single-antigen readouts was strongly influenced by both the antigen type and cut-off value and ranged widely [0.8% (95% CI 0.4–1.5%)–7.5% (95% CI 6.0–8.9%)]. A multi-antigen approach requiring partial agreement between RBD and N or S1 readouts (RBD&N\|S1 rule) was less affected by cut-off selection, resulting in robust seroprevalence estimation [0.6% (95% CI 0.3–1.1%)–1.2% (95% CI 0.7–2.0%)] and accurate identification of seroconverted individuals.Christos FotisNikolaos MeimetisNikos TsolakosMarianna PolitouKarolina AkinosoglouVaia PliakaAngeliki MiniaEvangelos TerposIoannis P. TrougakosAndreas MentisMarkos MarangosGeorge PanayiotakopoulosMeletios A. DimopoulosCharalampos GogosAlexandros SpyridonidisLeonidas G. AlexopoulosNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Christos Fotis Nikolaos Meimetis Nikos Tsolakos Marianna Politou Karolina Akinosoglou Vaia Pliaka Angeliki Minia Evangelos Terpos Ioannis P. Trougakos Andreas Mentis Markos Marangos George Panayiotakopoulos Meletios A. Dimopoulos Charalampos Gogos Alexandros Spyridonidis Leonidas G. Alexopoulos Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays
description	Abstract There is a plethora of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serological tests based either on nucleocapsid phosphoprotein (N), S1-subunit of spike glycoprotein (S1) or receptor binding domain (RBD). Although these single-antigen based tests demonstrate high clinical performance, there is growing evidence regarding their limitations in epidemiological serosurveys. To address this, we developed a Luminex-based multiplex immunoassay that detects total antibodies (IgG/IgM/IgA) against the N, S1 and RBD antigens and used it to compare antibody responses in 1225 blood donors across Greece. Seroprevalence based on single-antigen readouts was strongly influenced by both the antigen type and cut-off value and ranged widely [0.8% (95% CI 0.4–1.5%)–7.5% (95% CI 6.0–8.9%)]. A multi-antigen approach requiring partial agreement between RBD and N or S1 readouts (RBD&N\|S1 rule) was less affected by cut-off selection, resulting in robust seroprevalence estimation [0.6% (95% CI 0.3–1.1%)–1.2% (95% CI 0.7–2.0%)] and accurate identification of seroconverted individuals.
format	article
author	Christos Fotis Nikolaos Meimetis Nikos Tsolakos Marianna Politou Karolina Akinosoglou Vaia Pliaka Angeliki Minia Evangelos Terpos Ioannis P. Trougakos Andreas Mentis Markos Marangos George Panayiotakopoulos Meletios A. Dimopoulos Charalampos Gogos Alexandros Spyridonidis Leonidas G. Alexopoulos
author_facet	Christos Fotis Nikolaos Meimetis Nikos Tsolakos Marianna Politou Karolina Akinosoglou Vaia Pliaka Angeliki Minia Evangelos Terpos Ioannis P. Trougakos Andreas Mentis Markos Marangos George Panayiotakopoulos Meletios A. Dimopoulos Charalampos Gogos Alexandros Spyridonidis Leonidas G. Alexopoulos
author_sort	Christos Fotis
title	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays
title_short	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays
title_full	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays
title_fullStr	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays
title_full_unstemmed	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays
title_sort	accurate sars-cov-2 seroprevalence surveys require robust multi-antigen assays
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/858a40ad7d234e85a90d69d2e74774df
work_keys_str_mv	AT christosfotis accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT nikolaosmeimetis accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT nikostsolakos accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT mariannapolitou accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT karolinaakinosoglou accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT vaiapliaka accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT angelikiminia accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT evangelosterpos accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT ioannisptrougakos accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT andreasmentis accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT markosmarangos accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT georgepanayiotakopoulos accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT meletiosadimopoulos accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT charalamposgogos accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT alexandrosspyridonidis accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays AT leonidasgalexopoulos accuratesarscov2seroprevalencesurveysrequirerobustmultiantigenassays
_version_	1718395291729657856

Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays

Ejemplares similares